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Introduction
So far, the effectiveness of symptomatic-based treatments 
for  osteoarthritis  (OA)  is  only  small  to  moderate  [1]. 
Efforts to develop disease-modifying drugs have not yet 
succeeded in diminishing symptomatic OA [2]. Given the 
wide range of available treatments in OA and their small 
to  moderate  effectiveness,  better-targeted  treatment  is 
desirable.
Treatment guidelines for OA have stressed the need for 
research  on  clinical  predictors  of  response  to  different 
treatments [3,4]. For example, the OA guideline of the 
Royal  College  of  Physicians  specifically  mentions  the 
complexity of OA in terms of pain and range of structural 
pathology, that few useful subclassifications of OA exist 
with respect to targeted treatment, and that it is unclear 
in which way co-morbidity in patients with OA influences 
treatment outcome [4].
Rothwell [5] identified several situations where a search 
for clinically important heterogeneity of treatment effects 
should be considered: first, in case multiple pathologies 
underlie a clinical syndrome; and second, in diseases with 
different severity and/or at different stages, or where co-
morbidity is frequently present. Both situations apply to 
OA  patients;  however,  there  is  hardly  any  agreement 
about the classification of such OA subgroups.
Moreover, identifying clinical predictors of response to 
treatment is not simple. It is essential to use the correct 
methodology to identify such subgroups in order to avoid 
that some patients are erroneously deprived of certain 
treatments,  or  are  erroneously  assumed  to  have  an 
(better) effect from such treatment. Therefore, this over-
view  will  discuss  methodology  of  identifying  clinical 
predic  tors of response to different treatments, and pro-
pose the main OA subpopulations and give examples of 
how  specific  treatment  effects  in  these  subpopulations 
have been assessed.
Methods
This  overview  is  based  on  a  pragmatic  search  of  the 
litera  ture.  In  order  to  discuss  the  methodology,  we 
searched in the Medline library for articles on the subject 
‘subgroup analysis’ in combination with ‘treatment’ and 
‘methodology’;  a  short  overview  of  the  main  methods 
found and their implications are discussed, and summar-
ized in Table 1.
In order to give a classification of OA subpopulations, 
we searched the Medline library for articles on the com-
bination of ‘osteoarthritis’ and [phenotyp* OR subgroup* 
OR  subpopulation]  and  [treatment*  OR  therapy  OR 
intervention*].  Subgroups  mentioned  in  the  abstracts 
were classified under the subheadings phenotypes, struc-
tural and symptomatic stage, co-morbidity, and patient 
characteristics.  Finally,  we  searched  for  more  detailed 
information on these (kind of) subpopulations and for 
examples of subgroup analysis with respect to treatment 
effects. Atrophic hip OA and genotypes were not found 
but are added, and briefly discussed. The main categories 
are summarized in Table 2.
Methodology in testing for subgroup effects of 
treatment
Subgroup-specific trials are obvious for the different OA 
joint  groups,  and  for  treatment  specifically  aimed  at 
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© 2011 BioMed Central Ltdcertain OA subgroups, such as osteotomy for uni  com-
part  ment malaligned knee OA. However, to design such 
trials for every suspected subgroup for the available treat-
ments would take many years of research, and resources. 
Therefore,  subgroup  analyses  or  treatment  response 
analyses within trials are undertaken.
Prognostic factors
A first issue to be addressed in subgroup analysis is the 
difference between the subgroup factor as a prognostic 
factor and as an effect modifier of treatment response. 
Single arm trials (or assessing predictors of response in 
only  the  active  treatment  group)  identify  prognostic 
factors  and  might  wrongly  suggest  that  the  effect  of 
treatment is greater in certain subgroups than in others 
[6]. To be identified as a subgroup that shows a different 
effect of treatment compared with another subgroup, the 
subgroup factor should be identified as an effect modifier. 
This  means  that  the  treatment  interacts  with  the 
subgroup  factor  with  respect  to  treatment  outcome, 
showing another difference in outcome (effect) between 
treatment  A  and  B  in  the  specific  subgroup.  Conse-
quently, for such analyses a control group is needed.
Post hoc testing versus predefined testing
A  frequently  used  method  to  identify  subgroups  with 
respect to effect of treatment is a post hoc analysis. The 
main analyses for effect of treatment in a two-arm trial 
are repeated in certain subgroups and tested for signi-
ficance of effect. However, this kind of analysis includes a 
high risk of false results; type I as well as type II errors 
[7,8]. Post hoc tests should therefore be regarded as un-
reliable unless they can be replicated [5].
As outlined by the CONSORT statement, reporting on 
subgroup effects in trials should only be done when the 
subgroup to be tested is predefined in the protocol, and 
the number of subgroups to be tested should be limited to 
the absolute minimum. The subgroups should be based on 
previous explorative research or on theoretical con  sider-
ations, and the direction of the effects should be stated [5]. 
To  anticipate  equal  distribution  of  the  main  prog  nostic 
variables  over  the  treatment  arms  in  the  sub  groups, 
stratification of randomisation by the subgroup factor is 
advisable. In a predefined trial with subgroup testing the 
trial should be powered such that the expected effect, if 
present, should be detected in the smallest subgroup.
Subgroup-treatment interaction effect
A methodologically robust method is to test for a subgroup-
treatment  interaction  effect.  Such  analyses  assess  the 
statistical significance of the difference in effect between 
subgroups [7] by simply testing for a difference in treat-
ment effects making use of a standard normal approxi-
mation, or by including interaction terms in a regression 
model. Assessing interaction carries a much smaller risk 
of  false-positive  results.  This  kind  of  analysis  will  only 
show a positive result for interaction when the subgroup-
treatment interaction is very strong, or when the trial is 
Table 1. Key issues when assessing subgroup treatment effects
Prognostic factors are not necessarily treatment effect modifiers 
Post hoc subgroup effects in trials should be regarded as unreliable unless they can be replicated in dedicated trials or meta-analyses
When subgroup analysis is predefined in a trial, randomisation should be stratified by subgroup and the power should be adjusted to the smallest subgroup 
Testing for interaction effects in trials is more robust than subgroup analysis, but needs a well-powered study depending on the expected size of the interaction 
effect 
The number of subgroups should be limited to a minimum to avoid multiple testing
Combining trials for meta-analysis has the potential to search for subgroup effects. For reliable subgroup meta-analysis, individual trials have to supply 
subgroup effects and use stratified treatment randomization by subgroup, or supply the distribution of prognostic variables over the treatment arms in the 
subgroup 
Meta-analysis using individual patient data is a powerful method and the gold standard for assessing subgroup-treatment interaction effects
Table 2. Suggested main subgroups of OA in clinical 
research
OA phenotypes
  Joint site/joint compartment
  Localized or generalized osteoarthritis
  Structural osteoarthritis subtypes
  Pain phenotypes
Structural or symptomatic stage
  Pain severity
  Restricted motion 
  Radiographic severity 
  Effusion/synovitis 
  Bone marrow lesions
Co-morbidity
  Obesity
  Cardiovascular disease





  Treatment preference
  Psychosocial factors
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designed to detect the supposed subgroup-treat  ment inter-
actions, the sample size should be inflated fourfold when 
the  interaction  effect  is  equal  to  the  overall  treatment 
effect. When the interaction effect is only half of the overall 
treatment effect, the inflation factor is already 16 [8].
Meta-analysis of randomised controlled trials
A  solution  might  be  found  in  meta-analyses.  Meta-
regression, one of the methods used, aims to relate the 
treatment  effect  recorded  in  the  different  trials  to  the 
characteristics of those trials in which the study is the 
unit of analysis. Even if appropriate statistical methods 
are used, relations with averages of the patients’ charac-
teristics in the trials are potentially misleading [9], due to 
confounding, unequal distributions, or to lack of power. 
Another  method,  meta-analysis  dedicated  to  certain 
subgroups, might be possible when subgroup effects are 
reported, or when data on the subgroup effects can be 
retrieved from the authors. For a valid interpretation of 
these  results,  a  stratified  randomisation  by  subgroup 
factor in the individual trials is needed, or information on 
the  distribution  of  prognostic  variables  over  the  treat-
ment arms in the subgroup should be supplied.
Meta-analysis with individual patient data
The third method, a meta-analysis for quantifying inter-
action effects using individual patient data (IPD), might 
overcome  the  power  problem  in  individual  trials  and 
meta-regression  analysis.  A  meta-analysis  in  which  re-
analysis  of  all  IPD  can  be  accomplished  is  widely  con-
sidered to be the gold standard. Authors of the included 
trials can be requested to make available their IPD, and/or 
well-designed collaborative projects can be initiated. In a 
meta-analysis using IPD, in which the data of several trials 
are pooled, the interaction effects between sub  groups and 
treatment  can  be  reliably  assessed  and  poten  tial 
confounders can be adjusted for [10]. Essential for such an 
analysis is that the baseline data with respect to defining 
subgroups and confounders are obtained in similar ways
Osteoarthritis subpopulations
Phenotypes
The historical classification of OA in primary and secon  dary 
OA has been abandoned because OA is always secondary to 
something,  and  usually  to  a  combination  of  factors  [11]. 
Still, a way to define distinct phenotypes of OA could be 
based on the main risk factors and etiological factors [12]. 
Phenotypes can also be based on structural appearances, 
localization, site of manifestation, and on pain types.
Joint site
The different joint groups are generally seen as distinct 
phenotypes. For example, knee, hand, hip, and spine OA 
have different risk factors [13-15], and inheritance factors 
might be linked to joint-specific genes [16]. Even within 
these localizations there are distinct differences between, 
for example, localized thumb OA and nodal inter  phalan-
geal hand OA [17,18], and between patellofemoral OA 
only and multi-compartment knee OA [19,20]. In addi-
tion, the different joint sites can have different structural 
and symptomatic appearances [21]. In spinal OA, specific 
neurological  symptoms  like  neurogenic  claudication, 
numbness, tingling, or weakness can be present due to 
lumbar spinal stenosis [22]. Whether or not treatment 
effects are expected to differ between these specific joint 
sites might depend on the kind of treatment.
Examples
The  inflammatory  component  [21]  or  type  of  pain  [23] 
might differ between hip OA and knee OA. Indeed, one 
study reported a higher effectiveness of oral nonsteroidal 
anti-inflammatory drugs (NSAIDs) in knee than in hip OA 
based on a re-analysis of a large trial comparing NSAIDs 
to placebo in patients with hip or knee OA [24]. However, 
the authors compared the before and after effects in the 
NSAID group between hip and knee patients, and not the 
in-between effects of NSAIDs versus placebo between hip 
and knee patients. If the placebo effect is also stronger in 
knee OA patients, there may not be greater effectiveness of 
NSAIDs in knee OA. In two meta-analyses combining two 
and three studies, respectively, the difference in the effect 
of NSAIDs versus placebo between hip and knee OA was 
formally evaluated for interaction effects in a meta-analysis 
with IPD. The authors could not show better effectiveness 
of NSAIDs in knee OA patients than in hip OA patients 
[25,26]. However, the selected studies in these two meta-
analyses included patients with increased pain following a 
wash-out period after NSAIDs (known as the flare design); 
in this way only potential responders were included and a 
difference in effect may no longer be expected.
It was not known whether the positive effects of exer  cise 
for knee OA could be extrapolated to hip OA because 
exercise trials mostly included knee OA patients. In the 
trials combining knee and hip OA, the subgroups with 
hip  OA  were  often  too  small  for  reliable  subgroup 
analysis. Recently, Hernandez-Molina and colleagues [27] 
retrieved data from subgroups with hip OA in exercise 
trials that included both patients with hip OA and those 
with knee OA. With this meta-analysis in a site-specific 
subgroup the authors could confirm the effectiveness of 
exercise therapy in hip OA.
Generalized versus local osteoarthritis
The concept of generalized OA has been widely accepted 
[12]. Meta-analysis of genome-wide association studies 
confirmed  that  at  least  one  allele  is  linked  to  a  more 
systemic  initiation  of  OA  [28,29].  More  rare  forms  of 
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been linked to specific mutations [30]. Systemic acting 
treat  ments might be more efficacious in a joint that is 
part of a generalized OA than in a joint-specific local OA 
where  biomechanical  factors  may  largely  contribute  to 
the disease. In addition, a systematic review showed that 
knee OA as part of generalized OA showed faster pro-
gression than local knee OA [31]. Many different defini-
tions  for  generalized  OA  have  been  used.  Based  on 
formal  cluster  analysis  in  more  than  a  thousand  OA 
patients,  Dougados  and  colleagues  [32]  suggested  that 
generalized  OA  should  be  defined  as  the  presence  of 
bilateral  involvement  of  the  fingers,  or  involvement  of 
spine and both tibiofemoral joints. However, so far there 
is no agreed definition for generalized OA.
Examples
Rozendaal  and  colleagues  [33]  defined  beforehand  a 
subgroup analysis in patients with OA at more joint sites 
than the hip alone, in a trial assessing the effectiveness of 
glucosamine sulphate in patients with hip OA. The trial 
was also powered to assess symptomatic effects in the 
subgroups, and used a stratified treatment randomization 
for the subgroup generalized OA. The authors did not 
show any effect in this subgroup, but the effect was also 
absent in the total group.
Structural osteoarthritis subtypes
Whether or not atrophic versus hypertrophic OA, erosive 
versus  non-erosive,  and  concurrent  chondrocalcinosis 
should be seen as distinct etiological phenotypes or as a 
continuum of severity, or as being influenced by existing 
co-factors, is not yet entirely clear.
Atrophic osteoarthritis
OA can be classified as hypertrophic or atrophic accord-
ing to the presence or absence of osteophytes. A syste-
matic review showed strong evidence that the atrophic 
form  demonstrates  a  faster  progression  of  joint  space 
narrowing than in hypertrophic OA [34]. Conrozier and 
colleagues [35] suggested that atrophic hip OA might be 
due  to  a  relative  deficiency  in  the  synthesis  of  type  II 
collagen, which is needed for enchondral ossification in 
the formation of osteophytes.
Erosive osteoarthritis
Erosive OA appears to be a specific subgroup of hand OA 
with  worse  clinical  and  structural  outcomes.  The 
ESCISIT task force [36] postulated that erosive hand OA 
targets  interphalangial  joints  in  the  hand  and  shows 
radiographic subchondral erosion, which may progress to 
marked bone and cartilage attrition, instability and bony 
ankylosis.  This  kind  of  hand  OA  should  possibly  be 
treated  differently  because  of  the  major  inflammatory 
component in erosive hand OA. However, to date, only a 
few small pilot studies have specifically targeted erosive 
hand OA [37].
Chondrocalcinosis
Large calcium-containing crystal deposits in the joint 
can  be  detected  radiographically  and  is  called 
chondro  calcinosis (CC). This is seen in 19% of end-
stage knee OA, and in 10% of end-stage hip OA [38]. 
There  is  some  evidence  that  these  calcium 
pyrophosphate crystals are biologically active particles 
that  develop  in  the  setting  of  cartilage  damage,  but 
also  contribute  to  the  osteo  arthritis  process  [39]. 
Some  studies  suggest  that  OA  with  CC  may  differ 
from OA without CC in showing more osteo  phy  tosis 
and more inflammatory features [40], but whether or 
not  the  presence  of  CC  might  interact  with  various 
forms of treatment is not yet known. A recent study 
showed that CC is not associated with worsening of 
OA as defined by the progression on MRI [41].
Biomechanical deviations
Biomechanical deviations in the joint are known to be a 
risk factor for OA. A detrimental biomechanical influ-
ence  in  mal-aligned  varus  knees,  due  to  the  increased 
adduction moment in the knee, is widely recognized with 
respect to both initiation and progression of OA [42,43]. 
Femoral  head  abnormalities  (for  example,  slipped 
femoral capital epiphysis) are well-known risk factors for 
hip OA [44]. Major dysplasia of the hip results in early 
onset of hip OA with fast progression; however, minor 
dysplasia is also a risk factor for hip OA [45], and hip OA 
with supero-lateral migration of the femoral head shows 
faster progression [34].
Kinematics  in  a  joint  might  also  undergo 
unfavourable  change  due  to  joint  laxity  and 
neuromuscular  defici  en  cies.  Overall,  mechanical 
abnormalities in a joint are impor  tant risk factors for 
OA,  but  mechanical  abnor  malities  may  also  worsen 
(or  be  the  result  of)  an  osteo  arthritic  process  and 
become an important prognostic factor.
Injured joints
Local  joint  injury,  and  especially  meniscal  injury  or 
meniscal ectomy, is widely recognized as being associated 
with  the  development  of  knee  OA  [46].  Apart  from 
mechanical change in the knee due to these lesions, it is 
suggested  that  the  biology  in  the  knee  has  already 
changed  in  the  first  weeks  after  the  acute  injury; 
inflammatory processes in the initial phase are suggested 
to  induce  proteoglycan  loss  followed  by  subsequent 
collagen loss [47]. Both pathways might be involved in 
the initiation of post-traumatic OA with implications for 
possible preventive treatments.
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Lim and colleagues [48] performed a trial in which they 
included both mal-aligned and neutral positioned knee 
OA patients to assess the effect of quadriceps-strengthen-
ing exercises versus control treatment. Based on previous 
research, due to an increase of quadriceps strength they 
expected  progression  of  the  adduction  moment  in  the 
mal-aligned group. They powered the trial on interaction 
between  treatment  and  mal-alignment,  but  on  formal 
testing  found  no  such  interaction  effect  between 
treatment  and  mal-alignment  with  respect  to  their 
primary  outcome  (adduction  moment).  However,  they 
did find such an effect with repeated testing in one of the 
other five outcomes, indicating less pain relief of exercises 
in  mal-aligned  knees  than  in  neutral  knees.  Given  the 
reported  significance  for  the  interaction  effect  (P  < 
0.001), the subgroup with varus alignment seems to need 
another kind of (exercise) treatment.
Pain phenotypes
Pain  in  OA  differs  between  and  within  patients.  At 
present there are more or less consistent reports on an 
association between OA pain and the presence of joint 
effusion, or subchondral bone lesions [49]. Other sug  ges-
ted causes of pain in OA are bone attrition [50], neuro-
vascular invasion at the osteochondral junction [51], and 
ligament and tendon pathology [52]. How and whether 
these different sources of pain are reflected in different 
pain phenotypes is not well known. Night pain, pain at 
rest, and pain under load are the usual pain phenotypes 
mentioned in OA. In qualitative research, Hawker and 
colleagues  [23]  identified  two  main  types  of  pain  in 
people with OA of the knee and hip; a fairly constant (not 
disturbing)  background  pain,  and  a  less  frequent  but 
more intense and often unpredictable pain.
In addition, different pain mechanisms in OA can exist. 
Besides  the  nociceptive  pain,  neuropathic  pain  might 
develop, for which different screenings tools are available 
[53]. Central sensitization can also be present in chronic 
pain. Although the traditional assessment of central sensi-
ti  zation is complex, Nijs and colleagues [54] pro  posed a 
more  simple  assessment  to  be  used  in  clinical  practice. 
These different pain phenotypes in OA can be of impor-
tance to target pain treatment, but at present very little OA 
intervention research in this direction has been done.
Genotypes
Osteoarthritis genotypes
So far, genotyping of OA has aimed to identify pathways 
in OA and find new targets for treatment. However, in 
future  studies,  combinations  of  genetic  markers  might 
also  predict  the  risk  for  OA  and  identify  certain  sub-
groups with an increased risk for OA, identify subgroups 
of  OA  patients  with  fast  progression,  or  identify  OA 
patients susceptible for aseptic loosening of a prosthesis 
[55].  As  yet,  OA  genotyping  has  not  found  any  such 
clinical application.
Pain genotypes
A topic of increasing interest in recent OA research is the 
genetic variation in oa patients with respect to sensitivity 
for pain; a variation that might indicate a different need 
of  pain  management.  One  example  is  the  catechol-O-
methyltransferase polymorphism in which the sensitivity 
for  pain  is  increased  [56,57].  Also,  increasing  data  are 
available regarding several polymorphisms that influence 
the analgesic efficacy of nsaids, tramadol, codeine, and 
tryglyceric antidepressants, all with respect to drug meta-
bo  lism [58]. More research in this area is needed, but will 
probably focus on pain syndromes in general rather than 
specifically on OA pain.
Structural or symptomatic stage of osteoarthritis
Knowing that OA is a progressive disease, it is important 
to establish at what stage of the disease certain treatment 
will be most effective. For example, for intended disease-
modifying drugs it is not expected that these will have 
any effect in a stage with pronounced structural changes 
or  where  apparent  deleterious  mechanical  components 
are present [11].
Treatment effect might also depend on the severity of 
disease and specific symptoms. For example, the severity 
of pain, muscle weakness, restricted range of motion, and 
the  presence  or  not  of  intra-articular  joint  effusion  or 
synovitis in combination with a symptomatic flare might 
all influence the effects of different doses or types of pain 
medication,  anti-inflammatory  treatment,  and  exercise 
treatment or manual therapy.
Subchondral bone marrow lesions, an MRI sign that is 
seen in some OA patients and that can also disappear 
over time, represent foci of fibrosis and of osteonecrosis 
and  bone  remodelling  [59].  Some  of  these  are  micro-
fractures  of  the  trabecular  bone  at  different  stages  of 
healing. These bone marrow lesions have been shown to 
correlate with the severity of pain and with progression 
of the disease [60]. Therefore, people with and without 
these signs might respond differently to certain treatment 
modalities.
Examples
Pincus  and  colleagues  [61]  evaluated  the  comparative 
pain reduction of NSAIDs and acetaminophen in patients 
with  hip  or  knee  OA,  and  assessed  the  interaction 
between type of medication and a pooled severity score, 
based  on  radiographic  severity,  symptomatic  severity, 
and  number  of  involved  joints.  Significant  interaction 
effects were reported (without showing details), indicating 
similar effectiveness in the mildest group, but superior 
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same was found when assessing the separate indicators 
for severity, except for the radiographic ones.
In clinical practice intra-articular corticosteroid injec-
tions  are  indicated  in  patients  with  knee  effusion. 
However, there is limited evidence that such treatment 
might provide better effectiveness in those with effusions. 
Gaffney and colleagues [62] showed significantly better 
effect in the subgroup with clinical signs of effusion than 
in the subgroup without effusion. Another study showed 
no indication for better effects in the subgroup with signs 
of  effusion  [63],  and  a  third  study  even  found  better 
results  in  the  non-effusion  group  [64].  All  studies 
assessed  this  effect  only  in  the  active  treatment  group 
and, therefore, only identified prognostic factors and not 
necessarily predictors of differences in effect.
Co-morbidity
Major  well-known  co-morbidities  in  OA  patients  are 
cardiovascular  disease,  obesity,  and  diabetes.  However, 
sensory  impairments,  chronic  obstructive  pulmonary 
disease, and chronic low back pain are also frequent co-
morbidities  in  OA  patients  [65].  These  diseases,  their 
associated disabilities and/or medication may all interact 
with treatment for OA. For example, cardiovascular risk-
profile, renal function, glycaemic index history, and the 
use  of  anti-platelets  or  anti-hypertensive  drugs  will  all 
influence the choice of whether to treat or not with a 
NSAID and what type to use [66]. Musculoskeletal co-
morbidity  has  repeatedly  been  shown  to  influence 
severity  of  symptoms  [65,67,68];  coexistent  lower  back 
pain  has  also  been  shown  to  predict  future  pain  and 
disability in people with hip OA [69]. The presence of 
coexistent  lower  back  pain  or  buttock  pain,  often  in 
combination with spine OA, is also a possible reason for 
continued pain at that location after total hip arthroplasty 
and dissatisfaction with the surgery [70].
Concurrent depressive complaints are frequently seen 
in OA patients [71] and may also interfere with treatment 
or treatment compliance. However, the ways in which co-
morbid conditions in people with OA influence outcomes 
of treatment have hardly been explored [4].
A high body mass index is a well-known risk factor for 
knee OA, and to a lesser degree for hip OA and hand OA, 
and probably acts through a change in load distribution 
in  the  knee  [72],  and  systemic  and  local  inflammatory 
cytokines [73,74] released by the adipose tissue. It also 
seems, however, to influence severity of symptoms; over-
weight people more often experience morning stiffness in 
the knee and have more severe knee pain than those who 
are not overweight but with the same degree of radio-
graphic severity [75]. Although weight loss is a main goal 
in overweight OA patients, their weight might also have 
implications for other OA treatments.
Patient characteristics
Gender, age, educational level, and psychosocial charac-
teristics might all influence the effect of treatment. Above 
the age of 50 years, the incidence of OA rises steeply in 
women but less so in men, suggesting an association with 
changes  in  female  hormone  levels  during  menopause. 
However,  systematic  reviews  could  not  find  clear 
evidence for the assumed association between OA and 
aspects  concerning  the  fertile  period  and  menopause; 
only some evidence of a protective effect of unopposed 
oestrogen use for hip OA was found [76,77]. Recently, it 
was  found  that  symptomatic  postmenopausal  women 
clearly differ from those without vasomotor symptoms 
with respect to the risk for future cardiovascular disease 
[78].  This  might  also  be  the  case  with  respect  to  OA. 
Whether or how female hormone levels or other female 
characteristics interact with different kinds of treatment 
is not yet known.
Depending  on  the  type  of  intervention,  one  might 
consider the interaction of such characteristics with the 
treatment. For example, treatments that include a change 
of  lifestyle,  or  behavioural  treatment,  might  be  highly 
dependent on intrinsic motivation, or on psychological 
factors,  like  coping  style  or  level  of  locus  of  internal 
control [79]. Another well-known factor that influences 
treatment effect is the expectation the patient has about 
the treatment. A systematic review found that, in ran-
dom  ised open-label trials (back pain trials), about 57% of 
patients had a treatment preference, and that the effect 
size  increased  by  0.162  in  patients  with  a  treatment 
preference that also received this treatment compared to 
the ‘indifferent’ patients [80].
Examples
Veenhof and colleagues [81] assessed which hip or knee 
OA patients benefit most from a specific treatment in a 
randomised  controlled  trial  on  behavioural  graded 
activity therapy versus common exercise therapy. They 
tested for interaction effects in a multivariable model and 
found that patients with a relatively low level of physical 
functioning benefit more from behavioural therapy than 
from common exercise therapy. For a low level of internal 
locus of control the interaction with the kind of treatment 
was marginally significant.
Conclusions
Defining  subgroups  in  OA  remains  difficult,  especially 
because  the  etiopathogenesis  of  OA  is  not  yet  fully 
understood. It becomes even more complicated when the 
mechanism of action in treatments is not fully elucidated. 
In addition, several subgroups may well be derived from 
different  dimensions  of  the  disease  and  be  treatment 
specific and will, therefore, overlap each other. Because of 
this, a mutually exclusive classification of subgroups with 
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to achieve, but may also not be desirable.
In  addition,  when  defining  subgroups  in  clinical 
research, one should keep in mind that the ultimate goal 
of identifying a subgroup that is responsive to a specific 
treatment  is  that  clinicians  can  also  identify  these 
patients in practice. Should subgrouping become more 
costly,  invasive  or  time  consuming  than  the  treatment 
itself,  it  will  not  be  clinically  applicable  and  may  have 
only helped us to understand the mechanism of action of 
a specific type of treatment.
Because  OA  is  a  heterogeneous  disease,  identifying 
sub  groups for treatments is probably one of the promis-
ing ways forward in clinical research. This can only be 
achieved when the correct methodology to identify such 
subgroups is used, and the frequently reported post hoc 
testing is only regarded as hypothesis generating.
International collaborative initiatives aiming to define 
the  most  promising  treatment-specific  subgroups  are 
needed  and  consensus  should  be  reached  on  the  case 
definition of these subgroups. Such subgroup definitions 
can  be  used  for  predefined  subgroup  analysis  or  dedi-
cated trials, or for equal baseline measurement of these 
subgroup  factors  in  trials  to  facilitate  future  meta-
analyses,  as  well  as  initiatives  to  combine  IPD  from 
several  randomised  controlled  trials,  all  in  order  to 
generate appropriate recommendations for the effective 
treatment of various subgroups.
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